Financhill
Sell
46

VRTX Quote, Financials, Valuation and Earnings

Last price:
$453.24
Seasonality move :
0.96%
Day range:
$452.49 - $468.19
52-week range:
$377.85 - $519.88
Dividend yield:
0%
P/E ratio:
26.10x
P/S ratio:
10.75x
P/B ratio:
7.13x
Volume:
1.6M
Avg. volume:
1.6M
1-year change:
7.64%
Market cap:
$116.9B
Revenue:
$11B
EPS (TTM):
-$2.20

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VRTX
Vertex Pharmaceuticals
$2.8B $4.02 4.7% 15.92% $498.34
ABBV
AbbVie
$14.8B $2.26 5% 227.38% $204.90
GILD
Gilead Sciences
$7.2B $1.70 -0.47% 49.16% $101.24
LLY
Eli Lilly and
$13.4B $5.07 45.96% 90.83% $979.86
MRNA
Moderna
$941.1M -$2.73 -63.53% -79.68% $62.01
PFE
Pfizer
$17.3B $0.46 -3.36% 28.85% $31.18
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VRTX
Vertex Pharmaceuticals
$455.22 $498.34 $116.9B 26.10x $0.00 0% 10.75x
ABBV
AbbVie
$191.83 $204.90 $339B 79.93x $1.64 3.28% 6.03x
GILD
Gilead Sciences
$96.14 $101.24 $119.8B 1,068.22x $0.77 3.2% 4.25x
LLY
Eli Lilly and
$865.00 $979.86 $777.9B 73.87x $1.30 0.6% 17.36x
MRNA
Moderna
$30.93 $62.01 $11.9B -- $0.00 0% 2.37x
PFE
Pfizer
$25.53 $31.18 $144.7B 18.11x $0.43 6.62% 2.29x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VRTX
Vertex Pharmaceuticals
-- 1.257 -- 2.17x
ABBV
AbbVie
92.18% 0.524 -- 0.44x
GILD
Gilead Sciences
55.72% 0.444 22.27% 0.82x
LLY
Eli Lilly and
68.61% 1.194 -- 0.63x
MRNA
Moderna
-- -0.029 -- 3.95x
PFE
Pfizer
41.92% 0.484 -- 0.64x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VRTX
Vertex Pharmaceuticals
$2.5B $1.1B -3.23% -3.23% 39.12% $1.3B
ABBV
AbbVie
$10.7B -$1.5B 5.58% 58.92% -9.87% $5.2B
GILD
Gilead Sciences
$6B $3.1B 0.29% 0.64% 15.83% $4.2B
LLY
Eli Lilly and
$11.1B $5.7B 25.96% 66.4% 41.99% -$458.9M
MRNA
Moderna
$1.3B -$70M -17.44% -17.44% 1.46% -$1.7B
PFE
Pfizer
$11.9B $3.2B 5.04% 4.63% 4.1% $6.1B

Vertex Pharmaceuticals vs. Competitors

  • Which has Higher Returns VRTX or ABBV?

    AbbVie has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of -0.15%. Vertex Pharmaceuticals's return on equity of -3.23% beat AbbVie's return on equity of 58.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
    ABBV
    AbbVie
    70.89% -$0.02 $77.2B
  • What do Analysts Say About VRTX or ABBV?

    Vertex Pharmaceuticals has a consensus price target of $498.34, signalling upside risk potential of 9.36%. On the other hand AbbVie has an analysts' consensus of $204.90 which suggests that it could grow by 6.81%. Given that Vertex Pharmaceuticals has higher upside potential than AbbVie, analysts believe Vertex Pharmaceuticals is more attractive than AbbVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRTX
    Vertex Pharmaceuticals
    16 12 1
    ABBV
    AbbVie
    12 10 0
  • Is VRTX or ABBV More Risky?

    Vertex Pharmaceuticals has a beta of 0.413, which suggesting that the stock is 58.713% less volatile than S&P 500. In comparison AbbVie has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.122%.

  • Which is a Better Dividend Stock VRTX or ABBV?

    Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie offers a yield of 3.28% to investors and pays a quarterly dividend of $1.64 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. AbbVie pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VRTX or ABBV?

    Vertex Pharmaceuticals quarterly revenues are $2.9B, which are smaller than AbbVie quarterly revenues of $15.1B. Vertex Pharmaceuticals's net income of $913M is higher than AbbVie's net income of -$22M. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while AbbVie's PE ratio is 79.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 10.75x versus 6.03x for AbbVie. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRTX
    Vertex Pharmaceuticals
    10.75x 26.10x $2.9B $913M
    ABBV
    AbbVie
    6.03x 79.93x $15.1B -$22M
  • Which has Higher Returns VRTX or GILD?

    Gilead Sciences has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of 16.61%. Vertex Pharmaceuticals's return on equity of -3.23% beat Gilead Sciences's return on equity of 0.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
    GILD
    Gilead Sciences
    79.14% $1.00 $41.6B
  • What do Analysts Say About VRTX or GILD?

    Vertex Pharmaceuticals has a consensus price target of $498.34, signalling upside risk potential of 9.36%. On the other hand Gilead Sciences has an analysts' consensus of $101.24 which suggests that it could grow by 5.3%. Given that Vertex Pharmaceuticals has higher upside potential than Gilead Sciences, analysts believe Vertex Pharmaceuticals is more attractive than Gilead Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRTX
    Vertex Pharmaceuticals
    16 12 1
    GILD
    Gilead Sciences
    12 11 0
  • Is VRTX or GILD More Risky?

    Vertex Pharmaceuticals has a beta of 0.413, which suggesting that the stock is 58.713% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.179, suggesting its less volatile than the S&P 500 by 82.085%.

  • Which is a Better Dividend Stock VRTX or GILD?

    Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.2% to investors and pays a quarterly dividend of $0.77 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios VRTX or GILD?

    Vertex Pharmaceuticals quarterly revenues are $2.9B, which are smaller than Gilead Sciences quarterly revenues of $7.5B. Vertex Pharmaceuticals's net income of $913M is lower than Gilead Sciences's net income of $1.3B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Gilead Sciences's PE ratio is 1,068.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 10.75x versus 4.25x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRTX
    Vertex Pharmaceuticals
    10.75x 26.10x $2.9B $913M
    GILD
    Gilead Sciences
    4.25x 1,068.22x $7.5B $1.3B
  • Which has Higher Returns VRTX or LLY?

    Eli Lilly and has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of 32.59%. Vertex Pharmaceuticals's return on equity of -3.23% beat Eli Lilly and's return on equity of 66.4%.

    Company Gross Margin Earnings Per Share Invested Capital
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
    LLY
    Eli Lilly and
    82.24% $4.88 $45.4B
  • What do Analysts Say About VRTX or LLY?

    Vertex Pharmaceuticals has a consensus price target of $498.34, signalling upside risk potential of 9.36%. On the other hand Eli Lilly and has an analysts' consensus of $979.86 which suggests that it could grow by 13.28%. Given that Eli Lilly and has higher upside potential than Vertex Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRTX
    Vertex Pharmaceuticals
    16 12 1
    LLY
    Eli Lilly and
    15 6 0
  • Is VRTX or LLY More Risky?

    Vertex Pharmaceuticals has a beta of 0.413, which suggesting that the stock is 58.713% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.416, suggesting its less volatile than the S&P 500 by 58.369%.

  • Which is a Better Dividend Stock VRTX or LLY?

    Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.6% to investors and pays a quarterly dividend of $1.30 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VRTX or LLY?

    Vertex Pharmaceuticals quarterly revenues are $2.9B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Vertex Pharmaceuticals's net income of $913M is lower than Eli Lilly and's net income of $4.4B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Eli Lilly and's PE ratio is 73.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 10.75x versus 17.36x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRTX
    Vertex Pharmaceuticals
    10.75x 26.10x $2.9B $913M
    LLY
    Eli Lilly and
    17.36x 73.87x $13.5B $4.4B
  • Which has Higher Returns VRTX or MRNA?

    Moderna has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of 0.7%. Vertex Pharmaceuticals's return on equity of -3.23% beat Moderna's return on equity of -17.44%.

    Company Gross Margin Earnings Per Share Invested Capital
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
    MRNA
    Moderna
    72.29% $0.03 $11.9B
  • What do Analysts Say About VRTX or MRNA?

    Vertex Pharmaceuticals has a consensus price target of $498.34, signalling upside risk potential of 9.36%. On the other hand Moderna has an analysts' consensus of $62.01 which suggests that it could grow by 100.47%. Given that Moderna has higher upside potential than Vertex Pharmaceuticals, analysts believe Moderna is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRTX
    Vertex Pharmaceuticals
    16 12 1
    MRNA
    Moderna
    5 15 1
  • Is VRTX or MRNA More Risky?

    Vertex Pharmaceuticals has a beta of 0.413, which suggesting that the stock is 58.713% less volatile than S&P 500. In comparison Moderna has a beta of 1.589, suggesting its more volatile than the S&P 500 by 58.912%.

  • Which is a Better Dividend Stock VRTX or MRNA?

    Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VRTX or MRNA?

    Vertex Pharmaceuticals quarterly revenues are $2.9B, which are larger than Moderna quarterly revenues of $1.9B. Vertex Pharmaceuticals's net income of $913M is higher than Moderna's net income of $13M. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 10.75x versus 2.37x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRTX
    Vertex Pharmaceuticals
    10.75x 26.10x $2.9B $913M
    MRNA
    Moderna
    2.37x -- $1.9B $13M
  • Which has Higher Returns VRTX or PFE?

    Pfizer has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of 2.31%. Vertex Pharmaceuticals's return on equity of -3.23% beat Pfizer's return on equity of 4.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
    PFE
    Pfizer
    66.73% $0.07 $159.2B
  • What do Analysts Say About VRTX or PFE?

    Vertex Pharmaceuticals has a consensus price target of $498.34, signalling upside risk potential of 9.36%. On the other hand Pfizer has an analysts' consensus of $31.18 which suggests that it could grow by 22.11%. Given that Pfizer has higher upside potential than Vertex Pharmaceuticals, analysts believe Pfizer is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRTX
    Vertex Pharmaceuticals
    16 12 1
    PFE
    Pfizer
    7 13 1
  • Is VRTX or PFE More Risky?

    Vertex Pharmaceuticals has a beta of 0.413, which suggesting that the stock is 58.713% less volatile than S&P 500. In comparison Pfizer has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.808%.

  • Which is a Better Dividend Stock VRTX or PFE?

    Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.62% to investors and pays a quarterly dividend of $0.43 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VRTX or PFE?

    Vertex Pharmaceuticals quarterly revenues are $2.9B, which are smaller than Pfizer quarterly revenues of $17.8B. Vertex Pharmaceuticals's net income of $913M is higher than Pfizer's net income of $410M. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Pfizer's PE ratio is 18.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 10.75x versus 2.29x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRTX
    Vertex Pharmaceuticals
    10.75x 26.10x $2.9B $913M
    PFE
    Pfizer
    2.29x 18.11x $17.8B $410M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 111x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
65
ATEX alert for Feb 12

Anterix [ATEX] is down 0.72% over the past day.

Buy
87
GDS alert for Feb 12

GDS Holdings [GDS] is up 0.32% over the past day.

Sell
30
SPSC alert for Feb 12

SPS Commerce [SPSC] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock